TRUTAKNA received accelerated FDA approval for adults with IgA nephropathy, showing significant reductions in proteinuria and a favorable safety profile. The product will be available within weeks, supported by a robust commercial team and broad patient access programs.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.